Oncology

Displaying 1 - 10 of 18


Long-Lasting and Self-Sustaining Cell Therapy System

Researchers at Vanderbilt have created a novel drug delivery system using two distinct T-cell populations that interact to promote engraftment and persistence in pre-clinical models, increasing the efficacy of T-cell therapies. Furthermore, "booster" treatments can be administered months after the first dose to produce an expansion of antigen specific T cells. These advantages result in longer-term therapeutic efficacy and could reduce the number of treatments required. This system also represents a viable self-renewing platform for the delivery of biologic drugs in patients who would otherwise require frequent administration.


Licensing Contact

Cameron Sargent

615.343.2430

Small Molecule Mediated Transcriptional Induction of E-Cadherin and Inhibition of Epithelial-to-mesenchymal Transition


Licensing Contact

Tom Utley

615.343.3852
Therapeutics
Oncology

Small Molecule mGlu3 NAMs as Therapeutics for CNS Disorders

The Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) has a mission to promote the translation of advances in basic science towards novel therapeutics. They have recruited faculty and staff with experience at over 10 different pharmaceutical companies to ensure a diverse set of approaches, techniques and philosophies to advancing compounds. Together they aim to de-risk drug discovery programs.


Licensing Contact

Tom Utley

615.343.3852
Therapeutics

mGlu3 NAMs as Therapeutics for Chemoresistant Tumors

Targeting metabotropic glutamate receptor 3 (mGlu3) has been linked as a potential therapeutic to many neurological disorders and well as oncology through the use of dual specific mGlu2/3 Antagonists (LY341495, RO4491533, MGS0039, RO4988546).


Licensing Contact

Tom Utley

615.343.3852
Therapeutics

Primary Human Fibroblats Derived From Prostate Cancer Tissue and Normal Tissue

This research targets prostate cancer.


Licensing Contact

Karen Rufus

615.322.4295
Research Tools
Oncology
Cell Line

HCC2429 Human Lung Cancer Cell Line

This research targets HCC2429.


Licensing Contact

Karen Rufus

615.322.4295
Research Tools
Oncology
Cell Line

Screening Assay for Molecules That Alter Cell Cycle Rhythm

This research targets Cell Cycle.


Licensing Contact

Karen Rufus

615.322.4295
Research Tools
Oncology
Assays/Screening

Anti-p19 ARF Antibody

This research targets ARG(p19).


Licensing Contact

Mike Villalobos

615.322.6751

Inventors

Stephen Hann
Research Tools
Oncology
Antibody

Mouse Anti-Kaiso Monoclonal Antibody

This research targets Kaiso.


Licensing Contact

Karen Rufus

615.322.4295

Inventors

Albert Reynolds
Research Tools
Oncology
Antibody

Rabbit Anti-Fibroblast Specific Protein 1 Polyclonal Antibody

This research targets FSP1.


Licensing Contact

Karen Rufus

615.322.4295

Inventors

Eric Neilson
Research Tools
Antibody
Assays/Screening